{"title":"Physical exercise in combination with audiovisual stimulation alleviates cognitive and affective impairments in Alzheimer's disease model mice via restoring lysosomal membrane integrity.","authors":"Jun Jia, Guomin Xie, Wu Zheng, Chunshuang Xu, Yuxin Xia, Qiaoxia Hu, Binbin Xiang, Xinkai Zhou, Anqi Chen, Xiaoping Chen, Qinwen Wang, Yingsong Zhou, Shujun Xu","doi":"10.1186/s13195-026-02075-8","DOIUrl":"10.1186/s13195-026-02075-8","url":null,"abstract":"<p><strong>Background: </strong>Alzheimer's disease (AD) is a progressive disorder characterized by cognitive decline. Physical exercise and audiovisual stimulation have gained increasing concern for their potential to mitigate AD pathology. However, the therapeutic advantages of combining these interventions and the precise molecular mechanisms underlying these strategies need further demonstration.</p><p><strong>Objectives: </strong>This study aimed to assess the protective effects and underlying mechanisms of physical exercise combined with audiovisual stimulation on cognitive and affective functions, as well as on pathological alterations in AD mice.</p><p><strong>Methods: </strong>Both AD model mice established by injecting Aβ₄₂ oligomers into hippocampus and APP/PS1 AD transgenic mice were used. Mice were subjected to treadmill training, 40 Hz audio-visual stimulation, or a combination of these interventions, respectively. After the interventions, the cognitive and anxiety/depression-like behaviors were evaluated by novel object recognition, morris water maze, open field, tail suspension, or forced swimming, respectively. Quantitative proteomics combined with molecular analyses and transmission electron microscopy were used to systematically evaluate the underlying mechanism of multimodal interventions in AD model mice.</p><p><strong>Results: </strong>The multimodal intervention significantly prevented cognitive impairment and ameliorated anxiety/depression-like behaviors of APP/PS1 AD transgenic mice and AD model mice induced by injecting Aβ₄₂ oligomers, outperforming single-modality treatments. It markedly diminished hippocampal accumulation of β-amyloid (Aβ) and tau phosphorylation in AD mice. Multiple interventions also reversed synapse loss of AD mice. Proteomic analyses revealed that multimodal intervention exerted a more comprehensive restoration of dysregulated proteins in AD mice compared to single-modality interventions. The interventions have synergetic effects in decreasing inflammation reactions and restoring the autophagy-lysosomal function. Multimodal intervention upregulated the expression TFEB, and concurrently increased HSPA1L expression to restore lysosomal membrane integrity. The degradation function of lysosomes was also improved by multimodal intervention as revealed by the decreased LC3II/I ratio, reduced p62 level, as well as alleviated lysosome enlargement in AD mice. Upregulation of HSPA1L reversed the disruption of lysosome membrane integrity of AD transegenic mice, thereby reversed the increased accumulation of Aβ and cognitive defects of AD.</p><p><strong>Conclusion: </strong>Physical exercise and audiovisual stimulation exert synergistic effects in decreasing the inflammation reaction and maintaining autophagy-lysosomal homeostasis by increasing the biogenesis of lysosomes and restoring the integrity of lysosome membrane, thereby reducing Aβ deposition and cognitive defect of AD mice. This study highlights the ","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13425872/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148051991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"EEG biomarkers can predict early-stage Alzheimer's disease and correlate with intracerebral pathology: a multimodal machine learning study.","authors":"Zhi Geng, Wenqian Song, Chen Gao, Yun Zhu, Yue Wu, Bo Song, Haihua Guo, Jiayun Wu, Miao Fang, Yibing Yan, Shanshan Zhou, Panpan Hu, Yanghua Tian, Xingqi Wu, Kai Wang, Ling Wei","doi":"10.1186/s13195-026-02096-3","DOIUrl":"10.1186/s13195-026-02096-3","url":null,"abstract":"<p><strong>Background: </strong>Early recognition of Alzheimer's disease (AD) is crucial for timely intervention and delaying disease progression. Electroencephalogram (EEG) technology provides a direct reflection of the brain's dynamic activity. However, the relationship between potential EEG features and cognitive function in early-stage AD patients, as well as cerebrospinal fluid (CSF) pathological biomarkers, remains unclear.</p><p><strong>Methods: </strong>This study included 101 patients with mild cognitive impairment (MCI) and mild AD, alongside 69 healthy controls (HC) matched for gender, age, and educational attainment. Extracting EEG power spectral density (PSD) and microstates analysis features as training features for machine learning (ML), we employed five ML algorithms-Support Vector Machines (SVM), Logistic Regression (LR), Random Forests (RF), XGBoost, and LightGBM-for training and testing. Model performance was assessed using the area under the receiver operating characteristic curve (AUC). SHapley Additive exPlanations (SHAP) plots were employed to elucidate variable importance within the model, and sequential forward selection (SFS) was utilised to identify potential features. Correlation analysis and mediation analysis were conducted to investigate the relationships between EEG features, CSF pathological biomarkers, and cognitive function.</p><p><strong>Results: </strong>The LR model demonstrated the highest average predictive performance in the training set (mean AUC = 0.859 ± 0.059). The model incorporating PSD and microstates features demonstrated optimal predictive performance in the test set (AUC = 0.949, 95% CI: 0.877-1.000), outperforming any single-feature model. Based on SHAP and SFS analyses, six potential EEG indicators were identified: central region delta frequency band, central region theta frequency band, temporal region beta frequency band, microstate mean duration, microstate C duration, and the transition probability from microstate C to A. Mediation analysis revealed a significant negative correlation between central region theta frequency band and CSF Aβ₁₋₄₂ levels (r = - 0.31, p = 0.015), and the central region theta frequency band mediated the relationship between Aβ₁₋₄₂ levels and Mini-Mental State Examination (MMSE) scores (indirect effect = 0.0007, 95% CI: 0.0001-0.0013).</p><p><strong>Conclusion: </strong>The combined application of EEG and ML enables efficient classification diagnosis of early-stage AD, and EEG is correlated with intracerebral pathological biomarkers and cognitive impairment.</p>","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13425775/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148051981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alexandra L Clark, Elizabeth Valocchi, Makenna B McGill, Francesca V Lopez, Catherine Chanfreau-Coffinier, Kelsey R Thomas, Dylan J Jester, Mark W Logue, Victoria C Merritt
{"title":"Examining the additive risk of TBI and comorbid conditions on dementia in military veterans: a retrospective cohort study.","authors":"Alexandra L Clark, Elizabeth Valocchi, Makenna B McGill, Francesca V Lopez, Catherine Chanfreau-Coffinier, Kelsey R Thomas, Dylan J Jester, Mark W Logue, Victoria C Merritt","doi":"10.1186/s13195-026-02086-5","DOIUrl":"10.1186/s13195-026-02086-5","url":null,"abstract":"<p><strong>Background: </strong>Although traumatic brain injury (TBI) has been identified as a risk factor for Alzheimer's disease and related dementias (ADRD), not all studies have shown a clear link between TBI and ADRD, suggesting that the relationship between TBI and ADRD is complex, nuanced, and likely influenced by a multitude of factors. The purpose of this retrospective cohort study was to examine interactions between TBI history and co-occurring health conditions and health behaviors on 10-year incidence of ADRD among Veterans enrolled in the VA Million Veteran Program (MVP).</p><p><strong>Methods: </strong>Participants (N = 245,949) included Veterans aged ≥ 65 years at study enrollment who completed the MVP Baseline Survey and had VA electronic health record (EHR) data. Participants were followed from the date of MVP enrollment until the earliest ADRD diagnosis, death, or last visit date before the end of the observation period (January 2011 through September 2021). TBI status (TBI + vs. TBI-) and health conditions/health behaviors were characterized using a combination of MVP survey and EHR data. ADRD status (ADRD + vs. ADRD-) was based on a validated algorithm using EHR-extracted ICD codes. Cox proportional hazards regression analyses adjusted for age, sex, and education were used to assess the association between each health condition/health behavior and the hazard of ADRD in the TBI + and TBI- groups. Additive interactions between TBI and health conditions/health behaviors were tested using the relative excess risk due to interaction (RERI) statistic.</p><p><strong>Results: </strong>Among Veterans with a TBI history (n = 7,613), 12.16% developed ADRD over 10 years of follow-up; among those without TBI (n = 238,336), 4.32% developed ADRD. RERI analyses showed significant additive TBI by health condition/health behavior interactions for depression (RERI = 1.55, 95% CI = 0.96-2.15), heart attack/coronary artery disease (RERI = 0.76, 95% CI = 0.29-1.24), and physical inactivity (RERI = 0.58; 95% CI = 0.10-1.05), such that ADRD risk in Veterans with TBI was increased for those with these health conditions/health behaviors compared to those without.</p><p><strong>Conclusions: </strong>Findings suggest that ADRD risk following TBI may be heightened in the presence of certain health conditions/health behaviors, highlighting targeted areas of intervention for potentially mitigating adverse late-life outcomes in Veterans with a history of TBI.</p>","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13403857/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148051961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sergio Escamilla, Carlos Avilés-Granados, Carmen Márquez-Marco, Maximilian Keller, Irene Sánchez-Domínguez, Inmaculada Cuchillo-Ibáñez, Fernando Aguado, Henrik Zetterberg, Claus U Pietrzik, Javier Sáez-Valero
{"title":"Meprin-β levels are increased in the brain and the cerebrospinal fluid of Alzheimer's disease patients.","authors":"Sergio Escamilla, Carlos Avilés-Granados, Carmen Márquez-Marco, Maximilian Keller, Irene Sánchez-Domínguez, Inmaculada Cuchillo-Ibáñez, Fernando Aguado, Henrik Zetterberg, Claus U Pietrzik, Javier Sáez-Valero","doi":"10.1186/s13195-026-02092-7","DOIUrl":"10.1186/s13195-026-02092-7","url":null,"abstract":"<p><p>The aim of this study is to assess the levels of meprin-β, an alternative β-secretase in the brain and cerebrospinal fluid of subjects suffering Alzheimer's disease. The full-length zymogen and the active species of meprin-β were characterized by immunoblotting and immunoprecipitation using ectodomain N-terminal and C-terminal antibodies. We examined meprin-β changes in extracts from Alzheimer's frontal cortex (n = 13, Braak stages I-II; n = 12, Braak stages III-IV; n = 12, Braak stages V-VI) compared with controls (n = 14), as well as in cerebrospinal fluid samples from Alzheimer's patients (n = 15) or non-Alzheimer's controls (n = 15). Cerebrospinal fluid meprin-β levels were also determined in 19-month old TgF344-AD and wild-type rats. Brain and cerebrospinal fluid from a Mep1b-null mouse served to characterize the specificity of the immunoreactive bands for meprin-β. Human induced pluripotent stem cell (iPSC)-derived neuronal cultures were treated with 2 μM Aβ42 for 24 h. We found that meprin-β is present in human brain extracts and cerebrospinal fluid as several distinct species, attributed to the zymogen and the mature species. These species were absent in brain and cerebrospinal fluid from a Mep1b-null mouse. No fragments of meprin-β were detected in brain extract, either in cerebrospinal fluid. Only the mature forms of meprin-β are increased in frontal cortex extracts (from Braak V-VI), but not the zymogen. The MEP1-B mRNA levels are increased in Braaks III-IV and V-VI compared with controls. The meprin-β species are increased in human neuronal cultures treated with Aβ42. Finally, we demonstrated elevated levels of the mature meprin-β in the cerebrospinal fluid of patients with Alzheimer's disease and in TgF344-AD rats. Our data support a role of meprin-β in Alzheimer's pathology.</p>","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13425949/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148051994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Elizabeth McKiernan, Peter Swann, Elijah Mak, Maria Prats-Sedano, George Savulich, Allison Bentley, Guy Williams, Li Su, John T O'Brien
{"title":"Seven tesla MRI reveals amygdala and hippocampal subfield atrophy in dementia with Lewy bodies.","authors":"Elizabeth McKiernan, Peter Swann, Elijah Mak, Maria Prats-Sedano, George Savulich, Allison Bentley, Guy Williams, Li Su, John T O'Brien","doi":"10.1186/s13195-026-02091-8","DOIUrl":"10.1186/s13195-026-02091-8","url":null,"abstract":"<p><p>The 7T-DLB study investigated whether atrophy of individual hippocampal and amygdala subfields is present in dementia with Lewy bodies (DLB) as well as in Alzheimer's disease (AD) in which it has previously been established. MRI at standard clinical and research field strengths may have insufficient resolution to reveal the presence of atrophy in these regions in DLB; seven tesla MRI is ideally placed to examine subtle volumetric differences in these brain areas due to increased signal to noise ratio and tissue contrast.In this prospective, cross-sectional, seven tesla imaging study, 20 participants with probable DLB underwent MRI, clinical assessment, and cognitive testing, alongside a patient comparison group of 25 participants with probable AD, and 19 healthy controls. Scans were segmented using FreeSurfer automated pipelines. Hippocampal and amygdala subfield volumes were compared between diagnostic groups using a generalised linear model with age, sex, education, and total intracranial volume as covariates. Associations between volumes and cognition were examined using Kendall's tau. Exploratory analyses investigated associations between subfield volumes and visual hallucinations scores, and in a sub-set of 41 participants (DLB = 13, AD = 17, controls = 11), with plasma ptau-217 concentrations.Four (of 13) hippocampal subfields (molecular layer, subiculum, presubiculum, and entorhinal cortex) and five (of nine) amygdala subfields (accessory basal, central, medial and cortical nuclei, and anterior amygdaloid area) were significantly smaller in DLB compared to controls (p<sub>FDR</sub><0.05). In DLB, significant correlations between subfield volumes and Addenbrookes Cognitive Examination Scores were found for seven hippocampal subfields (Cornu Ammonis (CA)1, CA2/3, CA4, molecular layer, dentate gyrus, hippocampal amygdala transition area, and presubiculum), and five amygdala subfields (basal, accessory basal, central, cortical, and cortico-amygdala transition area) (all p<sub>FDR</sub><0.05). Exploratory analyses suggest that amygdala subfield volumes may be associated with visual hallucinations, though these provisional findings require replication.We conclude that structural seven tesla MRI reveals volumetric differences in individual hippocampal and amygdala subfields between DLB and controls, as well as between AD and controls where they have previously been described. Atrophy of individual subfields may potentially help explain the presence of cognitive and non-cognitive symptoms in DLB.</p>","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13404107/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148040756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
N Reijner, M Riscado Ramos, E Jacobs, D V Toen, B Tijms, A J M Rozemuller, L van der Weerd, F Barkhof, W D J van de Berg, L E Jonkman
{"title":"T1-weighted/T2-weighted ratio reflects microstructural changes in Alzheimer's disease.","authors":"N Reijner, M Riscado Ramos, E Jacobs, D V Toen, B Tijms, A J M Rozemuller, L van der Weerd, F Barkhof, W D J van de Berg, L E Jonkman","doi":"10.1186/s13195-026-02093-6","DOIUrl":"10.1186/s13195-026-02093-6","url":null,"abstract":"<p><strong>Background: </strong>The T1-weighted/T2-weighted ratio (T1w/T2w-ratio) has been considered as a relatively simple neuroimaging approach to map myelin content in the aging and diseased brain. However, we hypothesize that any process affecting the tissue microstructural integrity also contributes to observed changes in the T1w/T2w-ratio. Here, we aim to evaluate the ability of T1w/T2w-ratio to detect microstructural changes, specifically within the paradigm of Alzheimer's disease (AD).</p><p><strong>Methods: </strong>Postmortem in-situ T1-weighted and T2-weighted MRI scans of 27 control and 51 AD brain donors were processed into standardized T1w/T2w-ratio images and parcellated into cortical regions according to the brainnetome atlas. Using an identical pipeline, antemortem MRI scans of 9 AD cases were processed. Immunohistochemical staining and digital quantification were performed for amyloid-beta (4G8), phosphorylated tau (AT8), neuro-axonal damage (NfL), myelin (PLP), microglia (IBA1), and iron (Meguro) in 9 cortical regions. Data was analysed using linear mixed models.</p><p><strong>Results: </strong>Whole cortex T1w/T2w-ratio was 15% lower in AD compared to controls and was 13% lower in the hippocampus of typical AD compared to atypical AD clinical phenotypes. Additionally, a strong correlation was found between antemortem and postmortem T1w/T2w-ratios (r = 0.85). Whole-brain associations between T1w/T2w-ratio and histological changes were found in both control and AD patients: T1w/T2w-ratio associated with myelin density (Controls: β = 0.229; AD: β = 0.312) and microglia density (Controls: β=-0.090; AD: β=-0.496). In AD but not in controls, T1w/T2w-ratio associated with amyloid-beta (β = 0.233), phosphorylated tau (β=-0.220), and neuro-axonal damage (β = 0.170). Iron load showed contrasting associations in controls and AD (Controls: β=-0.359; AD: β = 0.154).</p><p><strong>Conclusion: </strong>The findings in this study suggest that the T1w/T2w-ratio is mainly associated with myelin density in healthy controls, but is a broader indicator of microstructural integrity in Alzheimer's disease, where it additionally largely associates with accumulation of amyloid-beta, phosphorylated tau and neuro-axonal damage. Therefore, the T1w/T2w-ratio is not a myelin-specific marker in AD, but could be a valuable neuroimaging tool for tracking longitudinal microstructural changes when interpreted alongside established AD pathology biomarkers.</p>","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13404876/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148040800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Myuri Ruthirakuhan, Maya Mills, Paul Rosenberg, Norman Haughey, Jacobo Mintzer, Olga Brawman-Mintzer, Suzanne Craft, Nathan Herrmann, Alan J Lerner, Allan I Levey, Prasad R Padala, Anton Porsteinsson, Christopher H van Dyck, David Shade, Krista L Lanctôt
{"title":"Uncovering lipid biomarkers linked to methylphenidate efficacy in treating apathy in Alzheimer's disease: insights from the ADMET 2 trial.","authors":"Myuri Ruthirakuhan, Maya Mills, Paul Rosenberg, Norman Haughey, Jacobo Mintzer, Olga Brawman-Mintzer, Suzanne Craft, Nathan Herrmann, Alan J Lerner, Allan I Levey, Prasad R Padala, Anton Porsteinsson, Christopher H van Dyck, David Shade, Krista L Lanctôt","doi":"10.1186/s13195-026-02055-y","DOIUrl":"10.1186/s13195-026-02055-y","url":null,"abstract":"<p><strong>Background: </strong>Apathy is a prevalent neuropsychiatric symptom (NPS) in Alzheimer's disease (AD), linked to functional impairment and reduced quality of life. The Apathy in Dementia Methylphenidate Trial 2 (ADMET-2) found methylphenidate (MPH) had modest efficacy for treating apathy, but treatment responses varied. MPH blocks dopamine and noradrenaline transporters, inhibiting dopamine and noradrenaline reuptake. Lipids are closely tied to monamine transporter function through their structural and signaling roles in neurotransmission, neuroinflammation, and synaptic plasticity. This study aimed to identify lipid species associated with MPH response and explore lipid pathway disruptions in responders versus non-responders.</p><p><strong>Methods: </strong>Participants from ADMET-2 with baseline lipidomic data were included. Responders were defined by a ≥4-point improvement on the Neuropsychiatric Inventory Apathy subscale (NPI-A), or moderate-to-marked improvement on the ADCS-Clinicians Global Impression-Change (ADCS-CGIC). Baseline plasma samples underwent lipidomic profiling. Sparse Partial Least Squares Discriminant Analysis (sPLS-DA) in the MPH group was used to identify lipid species distinguishing responders from non-responders. Model performance was evaluated by area under the curve (AUC). Identified lipid species were analyzed in MetaboAnalyst for pathway enrichment. A secondary analysis in the placebo group assessed specificity of findings to MPH.</p><p><strong>Results: </strong>Of the 43 MPH-treated participants, 28 were NPI-apathy responders, and 10 were ADCS-CGIC responders. The PLS-DA model achieved robust discrimination between responders and non-responders (NPI-apathy: AUC = 0.82 +/- 0.05; ADCS-CGIC: AUC=0.84 +/- 0.07). Pathway analysis revealed disruptions in ceramide, phosphosphingolipid, and glycosphingolipid metabolism for NPI-apathy responders, and ceramide and glycosphingolipid metabolism for ADCS-CGIC responders. In 55 placebo-treated participants (30 NPI-apathy responders), an AUC of 0.79 +/- 0.05 was achieved, with pathway analysis indicating disruption in glycosphingolipid metabolism only.</p><p><strong>Conclusions: </strong>This study demonstrates the utility of lipidomic profiling in identifying biomarkers of response to MPH in AD patients with apathy. The identified lipidomic species are broadly related to monoamine transporter function, reflecting their role in neurotransmission and synaptic plasticity. While glycosphingolipid metabolism appears broadly linked to changes in apathy, disruptions in ceramide and phospholipid metabolism may be specific to MPH treatment. Further study of these pathways may offer insights into the molecular mechanisms underlying apathy and treatment response, and could inform future biomarker-guided interventions.</p>","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13540924/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148013168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hanxiao Xue, Sheng Bi, Meixi Wang, Xiaohua Zhu, Feng Wang, Yong Wang, Yujie He, Yan Wang, Xiaocao Liu, Bixiao Cui, Na Li, Zhilian Zhao, Chun Zhang, Liyong Wu, Zhigang Qi, Shaozhen Yan, Jie Lu
{"title":"Optimizing cutoffs for clinical interpretation of brain amyloid status using PET/MRI: a multisite study.","authors":"Hanxiao Xue, Sheng Bi, Meixi Wang, Xiaohua Zhu, Feng Wang, Yong Wang, Yujie He, Yan Wang, Xiaocao Liu, Bixiao Cui, Na Li, Zhilian Zhao, Chun Zhang, Liyong Wu, Zhigang Qi, Shaozhen Yan, Jie Lu","doi":"10.1186/s13195-026-02071-y","DOIUrl":"10.1186/s13195-026-02071-y","url":null,"abstract":"<p><strong>Background: </strong>Amyloid-β PET (Aβ-PET) imaging is playing an increasingly important role in the diagnosis and treatment of Alzheimer's Disease (AD). The Centiloid (CL) scale has been developed to standardize the measurements of Aβ PET imaging. Previous CL threshold settings were based on PET/CT, while our team's preliminary study found that CL values from PET/MRI are higher than those from PET/CT. Therefore, there is an urgent need to establish clinical interpretation cutoffs for Aβ status via PET/MRI to facilitate application in clinical practice.</p><p><strong>Methods: </strong>The clinical performance of Aβ PET/MRI and cerebrospinal fluid biomarkers were evaluated in a multisite cohort of 720 participants. Aβ-PET scans were visually read and quantified using CL method. A two-cutoff approach identified thresholds maintaining > 90% sensitivity/specificity and ≤ 20% intermediate cases, selected by maximal Youden index. Group comparisons of cerebrospinal fluid biomarkers and cognition used generalized linear models adjusted for age and sex.</p><p><strong>Results: </strong>The two-cutoff approach categorized Aβ-PET status as negative (CL ≤ 18.7), gray-zone (18.7-44.2), and positive (CL > 44.2). In Xuanwu cohort, it achieved an accuracy of 94.1%, a positive predictive value of 97.4%, a negative predictive value of 86.1%. In External cohort, the accuracy was 97.4%, positive predictive value 98.5%, negative predictive value 90.8%. Patients in the gray-zone group had lower cerebrospinal fluid(CSF) Aβ-42, Aβ-42/40 levels and a higher P-tau/Aβ-42 ratio.</p><p><strong>Conclusions: </strong>This study established optimal CL-cutoff, providing a clinically applicable framework for interpreting Aβ PET/MRI findings. Incorporating a two-cutoff system facilitates the tracking of the AD continuum and supports individualized therapeutic decision-making.</p>","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13403643/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148004308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Andrea E Zülke, Melanie Luppa, Christian Sander, Ronny Baber, Ronald Biemann, Kerstin Wirkner, Samira Zeynalova, Silke Zachariae, Milica Matijevic, Christoph Engel, Nigar Reyes, Andreas Hinz, Heide Glaesmer, Matthias L Schroeter, A Veronica Witte, Arno Villringer, Markus Löffler, Carol Brayne, Steffi G Riedel-Heller
{"title":"Prevalence and associated factors of subjective cognitive decline (SCD Plus): a cross-sectional analysis of three population-based European cohorts.","authors":"Andrea E Zülke, Melanie Luppa, Christian Sander, Ronny Baber, Ronald Biemann, Kerstin Wirkner, Samira Zeynalova, Silke Zachariae, Milica Matijevic, Christoph Engel, Nigar Reyes, Andreas Hinz, Heide Glaesmer, Matthias L Schroeter, A Veronica Witte, Arno Villringer, Markus Löffler, Carol Brayne, Steffi G Riedel-Heller","doi":"10.1186/s13195-026-02087-4","DOIUrl":"10.1186/s13195-026-02087-4","url":null,"abstract":"<p><strong>Background: </strong>Subjective cognitive decline (SCD) is considered an early preclinical marker for Alzheimer's disease (AD). However, prevalence estimates vary widely due to inconsistent definitions. SCD Plus criteria were proposed by experts to improve specificity for preclinical AD. Population-based evidence on the prevalence and correlates of SCD Plus remains limited.</p><p><strong>Methods: </strong>Data from three population-based European cohorts (LIFE-Adult-Study, English Longitudinal Study of Ageing, and Cognitive Function and Ageing Study) comprising adults aged ≥ 60 years without dementia or marked cognitive impairment were harmonized to derive a common definition of SCD Plus based on available core criteria. Generalized linear models examined correlates of SCD Plus in pooled and study-specific analyses.</p><p><strong>Results: </strong>Among 18,795 participants (mean age (SD): 72.1 (6.8) years; 55.5% women), prevalence of SCD Plus, based on the harmonized operationalization, was 37.9% (33.3-53.7% across cohorts). In pooled analyses, SCD Plus was associated with higher education, depression, anxiety, hypertension, diabetes, heart disease, Parkinson's disease, and history of stroke, and inversely associated with smoking and better cognitive performance. Study-specific analyses additionally indicated associations with sleep and hearing-related problems, lower physical activity, thyroid disease, and personality traits (higher neuroticism and lower openness, agreeableness, conscientiousness).</p><p><strong>Discussion: </strong>SCD Plus was highly prevalent in three large European cohorts, assessed using a harmonized operationalization approach. Associations with several established, modifiable dementia risk factors underscore the relevance of SCD Plus for clinical risk assessment. Longitudinal studies are needed to determine whether the identified correlates influence subsequent cognitive decline in individuals with SCD Plus.</p>","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13220450/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148004295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Federico Coraglia, Giordano Cecchetti, Giulia Rugarli, Edoardo G Spinelli, Alma Ghirelli, Stefano Pisano, Elisa Canu, Massimo Filippi, Federica Agosta
{"title":"Plasma ApoE proteotyping for ApoE ε4 stratification in the anti-amyloid therapies era.","authors":"Federico Coraglia, Giordano Cecchetti, Giulia Rugarli, Edoardo G Spinelli, Alma Ghirelli, Stefano Pisano, Elisa Canu, Massimo Filippi, Federica Agosta","doi":"10.1186/s13195-026-02089-2","DOIUrl":"10.1186/s13195-026-02089-2","url":null,"abstract":"<p><strong>Background: </strong>Apolipoprotein E (ApoE) ε4 status informs risk stratification and safety management for anti-amyloid therapies, but genotyping typically requires dedicated procedures, longer turnaround times, and higher costs compared with automated laboratory assays. We evaluated an automated plasma approach for ε4 stratification based on proteotyping, the quantification of isoform-specific ApoE proteins to infer ApoE genotype.</p><p><strong>Methods: </strong>We retrospectively included 110 patients (mean age 67.82 ± 10.11 years, 49.1% female) of European ancestry with cognitive impairment across a broad diagnostic spectrum, including 68 AD-spectrum cases, 29 with subjective symptoms, and 16 with other etiologies. ApoE genotyping identified 57 ε4 non-carriers (51.8%), 44 heterozygous carriers (40.0%), and 9 homozygous carriers (8.2%). ApoE4 and total ApoE (PanApoE) were measured on Lumipulse and the ApoE4/PanApoE ratio (ApoE ratio) was derived.</p><p><strong>Results: </strong>The ratio showed excellent separation across genotypes in our cohort. For ε4 carrier identification, both the ratio and ApoE4 achieved an AUC of 1.00 (95% CI 1.00-1.00), whereas PanApoE showed poor discrimination (AUC 0.30, 95% CI 0.20-0.40), reflecting lower PanApoE levels in ε4 carriers. The ratio also accurately distinguished heterozygotes from homozygotes (AUC 1.00, 95% CI 1.00-1.00).</p><p><strong>Conclusions: </strong>Automated plasma ApoE proteotyping mirrored genetic ε4 status. The ApoE ratio provided complete genotype separation, supporting its use for individual-level stratification. These findings should be interpreted cautiously considering the retrospective single-center design and the limited number of ApoE ε4 homozygotes, and require validation in larger, independent cohorts.</p>","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13403392/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147986223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}